In CML, TKIs target the abnormal BCR::ABL1 protein that causes uncontrolled CML cell growth and block its function, causing the CML cells to die. The first therapy given for a disease is called initial or first-line treatment. The following four TKI drugs are approved as first-line treatment for chronic phase CML:
The page provides an overview of CML and CML treatment, or secondary drug resistance where the body loses its response to a medication over time.
In CML, TKIs target the abnormal BCR::ABL1 protein that causes uncontrolled CML cell growth and block its function, causing the CML cells to die. The first therapy given for a disease is called initial or first-line treatment. The following four TKI drugs are approved as first-line treatment for chronic phase CML:
The drug Imatinib has revolutionized the treatment of CML and has become the gold standard of care in CML for it is a highly targeted BCR-ABL tyrosine kinase
The introduction of TKIs for the initial treatment of CML has dramatically improved overall survival of younger CML patients. All cancer drugs described in
1. Introduction to Chronic Myeloid Leukemia (CML) 2. The Role of Clinical Trials in CML Treatment 3. Types of Clinical Trials for CML Treatment
Targeted therapies are typically used first in CML treatment. These are drugs that attack a specific part of the cancer cell to kill it. In the case of CML
How is CML treated? Targeted therapy drugs are the main treatment for chronic myeloid leukemia (CML), but some patients might also need other treatments.
A hot topic in the treatment landscape of chronic myeloid leukemia (CML) When you think about the landscape of CML, you think about which drugs
Comments
4*